Professional
Added to YB: 2026-01-23
Pitch date: 2025-10-09
LQDA [bullish]
Liquidia Corporation
+43.3%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Market Cap
$3.3B
Pitch Price
$24.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
-32.09
P/E
-26.30
EV/Sales
48.61
Sector
Pharmaceuticals
Category
growth
Liquidia Corporation ($LQDA) Investment Memorandum
LQDA: Yutrepia launch exceeding expectations w/ 2,284 estimated patients vs 550 reported, doctors prefer it over Tyvaso DPI for tolerability. Survey shows $2.50+ annualized EPS vs $24 stock. '327 patent risk on ILD indication but strong PAH uptake provides downside protection. Next-gen L606 entering Phase 3.
Read full article (9 min)